Brain NeoplasmsPhase 2NCT07903051
Lemborexant on Perioperative Sleep Quality in Patients With Brain Tumor Undergoing Surgery
A Phase 2 study testing Lemborexant 5 mg in people with Brain Neoplasms and Sleep Initiation and Maintenance Disorders, run by Beijing Tiantan Hospital.
Trial summary
This study tests whether lemborexant can improve perioperative sleep quality in people with brain tumor undergoing surgery. Adults with brain tumor scheduled for surgery may join. Participants will be randomly assigned to take lemborexant or a placebo the night before surgery. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Brain Neoplasms, Sleep Initiation and Maintenance Disorders
- What is being tested?
- Lemborexant 5 mg
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 112 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2026to 31 Dec 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled for elective craniotomy for brain tumor resection
- Age 18-65 years
- ASA physical status I-III
- Preoperative sleep disturbance, defined as Pittsburgh Sleep Quality Index (PSQI) score > 5
- Signed informed consent
Who cannot join
- Tumor located in the brainstem, thalamus, Wernicke's area, Broca's area, or frontal pole
- Severe neurological deficit with Karnofsky Performance Status (KPS) < 60
- Active epilepsy or poorly controlled epilepsy
- Chronic use of sedative-hypnotic medications
- Acute psychiatric illness
- Severe sleep apnea, COPD, severe daytime sleepiness (Epworth Sleepiness Scale [ESS] score ≥ 16), or history of narcolepsy and/or cataplexy
Show all 9Show fewer
- Severe hepatic or renal impairment
- Use of systemic moderate or strong CYP3A inhibitors and/or inducers within 1 week before surgery
- Any condition that, in the opinion of the principal investigator, precludes participation in the study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Lemborexant on Perioperative Sleep Quality in Patients With Brain Tumor Undergoing Surgery: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
This study tests whether lemborexant can improve perioperative sleep quality in people with brain tumor undergoing surgery. Adults with brain tumor scheduled for surgery may join. Participants will be randomly assigned to take lemborexant or a placebo the night before surgery. Researchers will measure sleep quality, anesthesia recovery, pain, postoperative recovery, and other outcomes.
- Being tested
- Lemborexant 5 mg, placebo
- Medical subject headings
- Brain Neoplasms, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lemborexant 5 mgDrug
Participants will receive a single oral dose of lemborexant 5 mg tablet on the night before brain tumor surgery.
placeboDrug
Participants will receive a single oral dose of matching placebo tablet on the night before brain tumor surgery.
| Study group | Role | What they receive |
|---|---|---|
| Lemborexant 5 mg | Experimental | Participants will receive a single oral dose of lemborexant 5 mg tablet on the night before brain tumor surgery. Receives: Drug: Lemborexant 5 mg |
| Placebo | Placebo comparator | Participants will receive a single oral dose of matching placebo tablet on the night before brain tumor surgery. Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Sleep Time (TST) on the Night Before Surgery
Total sleep time measured by a wrist-worn sleep monitoring device (Huawei smart band) during the night before brain tumor surgery. TST is defined as the total duration of sleep from sleep onset to final awakening, reported in minutes.
Measured: Night before surgery
Secondary outcomes (11)
Subjective sleep quality
Richards-Campbell Sleep Questionnaire (RCSQ) score. The RCSQ is a 5-item visual analog scale assessing sleep depth, sleep onset latency, awakenings, time spent awake, and overall sleep quality. Each item scored 0-100, total score is the mean of 5 items, range 0-100, higher scores indicate better sleep.
Measured: Preoperative day 1, Postoperative days 1-3 (assessed at 8:00-10:00 AM)
Objective sleep quality
Total sleep time measured by a wrist-worn sleep monitoring device (Huawei smart band) during the night of postoperative day 0. Reported in minutes.
Measured: Postoperative night 0 (20:00 to 08:00 next day) and Postoperative night 2 (20:00 to 08:00 next day)
Time to Extubation
Time from the end of surgery to extubation, defined as removal of the endotracheal tube. Reported in minutes.
Measured: Immediately after surgery
Time to Awakening
Time from the end of anesthesia to the first response to verbal command. Reported in minutes.
Measured: Immediately after surgery
Perioperative Anxiety Visual Analog Scale (VAS-A) Score
Anxiety Visual Analog Scale (VAS-A) score. The VAS-A is a 100-mm horizontal line anchored at 0 (no anxiety) and 100 (worst possible anxiety). The participant marks a point on the line corresponding to their anxiety level. Higher scores indicate greater anxiety. VAS-A score assessed upon entry to the operating room (before induction of anesthesia) and 1 hour after surgery.
Measured: Perioperative [Upon entry to the operating room (before induction of anesthesia), and 1 hour after surgery]
Postoperative Hospital Anxiety and Depression Scale (HADS) Score
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-rated questionnaire comprising two 7-item subscales: anxiety (HADS-A) and depression (HADS-D). Each item is scored from 0 to 3. Each subscale score ranges from 0 to 21, with higher scores indicating greater symptom severity.
Measured: Postoperative day 1 and 3 (assessed at 8:00-10:00 AM)
Postoperative pain measured by Pain Numeric Rating Scale (NRS) score
Pain Numeric Rating Scale (NRS) score. The NRS is an 11-point scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain intensity.
Measured: 1 hour after surgery, 24 hours, 48 hours and 72 hours after surgery.
Postoperative Quality of Recovery-15 (QoR-15)
Quality of Recovery-15 (QoR-15) score. The QoR-15 is a 15-item questionnaire assessing postoperative recovery across physical comfort, emotional state, and physical independence. Each item scored 0-10, total range 0-150, higher scores indicate better recovery quality.
Measured: Postoperative day 1
Incidence of Postoperative Delirium
Postoperative delirium will be assessed using the 3-Dimensional Confusion Assessment Method (3D-CAM). The 3D-CAM is a structured diagnostic interview that determines the presence or absence of CAM-defined delirium. Delirium incidence is the number of participants with at least one positive 3D-CAM assessment.
Measured: Within 3 days after surgery (assessed twice daily)
Pittsburgh Sleep Quality Index (PSQI) Score at 1 Month After Surgery
Pittsburgh Sleep Quality Index (PSQI) score. The PSQI is a 19-item self-rated questionnaire assessing sleep quality over the past month. Seven component scores are summed to yield a global score ranging from 0 to 21. Higher scores indicate worse sleep quality.
Measured: 1 month after surgery
Karnofsky Performance Status (KPS) Score at 1 Month After Surgery
Karnofsky Performance Status (KPS) score. The KPS is a clinician-rated scale ranging from 0 to 100, with scores assigned in 10-point increments. Higher scores indicate better functional status and greater ability to carry out daily activities independently. Assessed by a clinician at 1 month after surgery.
Measured: 1 month after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Nov 2026 (estimated)
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain NeoplasmsStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 112 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ruquan Han, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07903051
- Sponsor's protocol ID
- LEM2026-2
- Status last verified
- Oct 2026
- First submitted
- 13 Oct 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Lemborexant on Perioperative Sleep Quality in Patients With Brain Tumor Undergoing Surgery: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07903051
- Acronym / sponsor ID
- LEM2026-2
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 112 participants (estimated)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study tests whether lemborexant can improve perioperative sleep quality in people with brain tumor undergoing surgery. Adults with brain tumor scheduled for surgery may join. Participants will be randomly assigned to take lemborexant or a placebo the night before surgery. Researchers will measure sleep quality, anesthesia recovery, pain, postoperative recovery, and other outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lemborexant 5 mg | Experimental | Drug: Lemborexant 5 mgParticipants will receive a single oral dose of lemborexant 5 mg tablet on the night before brain tumor surgery. |
| Placebo | Placebo comparator | Drug: placeboParticipants will receive a single oral dose of matching placebo tablet on the night before brain tumor surgery. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients scheduled for elective craniotomy for brain tumor resection
- Age 18-65 years
- ASA physical status I-III
- Preoperative sleep disturbance, defined as Pittsburgh Sleep Quality Index (PSQI) score > 5
- Signed informed consent
Key exclusion criteria (9 listed)
- Tumor located in the brainstem, thalamus, Wernicke's area, Broca's area, or frontal pole
- Severe neurological deficit with Karnofsky Performance Status (KPS) < 60
- Active epilepsy or poorly controlled epilepsy
- Chronic use of sedative-hypnotic medications
- Acute psychiatric illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lemborexant 5 mgParticipants will receive a single oral dose of lemborexant 5 mg tablet on the night before brain tumor surgery. | Drug | Lemborexant 5 mg |
| placeboParticipants will receive a single oral dose of matching placebo tablet on the night before brain tumor surgery. | Drug | Placebo |
Primary outcome
Total Sleep Time (TST) on the Night Before Surgery
Time frame: Night before surgery
Total sleep time measured by a wrist-worn sleep monitoring device (Huawei smart band) during the night before brain tumor surgery. TST is defined as the total duration of sleep from sleep onset to final awakening, reported in minutes.
11 secondary outcomes
Subjective sleep quality
Time frame: Preoperative day 1, Postoperative days 1-3 (assessed at 8:00-10:00 AM)
Objective sleep quality
Time frame: Postoperative night 0 (20:00 to 08:00 next day) and Postoperative night 2 (20:00 to 08:00 next day)
Time to Extubation
Time frame: Immediately after surgery
Time to Awakening
Time frame: Immediately after surgery
Perioperative Anxiety Visual Analog Scale (VAS-A) Score
Time frame: Perioperative [Upon entry to the operating room (before induction of anesthesia), and 1 hour after surgery]
Postoperative Hospital Anxiety and Depression Scale (HADS) Score
Time frame: Postoperative day 1 and 3 (assessed at 8:00-10:00 AM)
Postoperative pain measured by Pain Numeric Rating Scale (NRS) score
Time frame: 1 hour after surgery, 24 hours, 48 hours and 72 hours after surgery.
Postoperative Quality of Recovery-15 (QoR-15)
Time frame: Postoperative day 1
Incidence of Postoperative Delirium
Time frame: Within 3 days after surgery (assessed twice daily)
Pittsburgh Sleep Quality Index (PSQI) Score at 1 Month After Surgery
Time frame: 1 month after surgery
Karnofsky Performance Status (KPS) Score at 1 Month After Surgery
Time frame: 1 month after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: Yes
Related trials for Brain Neoplasms
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Lemborexant 5 mg in people with Brain Neoplasms and Sleep Initiation and Maintenance Disorders, run by Beijing Tiantan Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ruquan Han, PhD (+86 59976660, ruquan.han@ccmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Sleep Time (TST) on the Night Before Surgery (time frame: Night before surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.